Polycystic ovary syndrome (PCOS) has been officially renamed to polycystic ovary metabolic syndrome (PMOS) following a comprehensive 10-year international research effort. The name change, announced by leading medical organizations, addresses decades of diagnostic confusion and aims to improve care for the estimated 8-13% of reproductive-aged women affected by the condition worldwide.
Global Impact of Polycystic Ovary Metabolic Syndrome
Estimated prevalence among reproductive-aged women by region
Source: International PCOS Guidelines, 2018 | Georgian Medical Journal News
Decade-Long Research Process Drives Name Change
The renaming initiative emerged from extensive consultation with healthcare providers and patients globally, according to research published in leading medical journals. Dr. Helena Teede, who led the international guidelines development process at Monash University, coordinated the effort that gathered input from over 14,000 participants across multiple continents.
The original name “polycystic ovary syndrome” proved problematic because not all patients develop cysts, and the term failed to capture the condition’s complex metabolic components. Clinical research has increasingly shown that PMOS involves significant insulin resistance, cardiovascular risk factors, and metabolic dysfunction beyond reproductive symptoms.
Addressing Diagnostic Confusion and Missed Cases
The name change directly addresses widespread diagnostic challenges that have plagued healthcare systems for decades. According to World Health Organization data, up to 70% of women with the condition remain undiagnosed, often experiencing years of symptoms before receiving appropriate care.
Dr. Elisabet Stener-Victorin, professor at the Karolinska Institute and co-author of the 2020 international evidence-based guidelines, emphasized that the metabolic focus in the new name helps healthcare providers recognize the condition’s systemic nature. The syndrome affects not only reproductive health but also increases risks for type 2 diabetes, cardiovascular disease, and mental health conditions.
Global Medical Organizations Endorse Change
The International PCOS Network, representing medical societies from over 40 countries, unanimously endorsed the name change following review of the extensive research evidence. The European Society of Human Reproduction and Embryology and the American Society for Reproductive Medicine have both updated their clinical guidelines to reflect the new terminology.
Implementation of PMOS terminology is expected to improve interdisciplinary care coordination, as the metabolic emphasis encourages collaboration between gynecologists, endocrinologists, and primary care physicians. Patient advocacy groups have welcomed the change, noting that it validates the complex, multi-system nature of their experiences.
The new name better reflects the condition’s metabolic complexity and may reduce diagnostic delays that currently average 2-3 years from symptom onset
— Dr. Helena Teede, Monash University (Nature Reviews Endocrinology, 2023)
Key takeaways
- PCOS officially renamed to PMOS after 10-year consultation with 14,000 healthcare providers and patients
- New name emphasizes metabolic aspects, potentially improving diagnosis of the 70% of cases currently missed
- International medical organizations have endorsed the change and updated clinical guidelines accordingly
Frequently asked questions
Why was PCOS renamed to PMOS?
The original name was misleading because not all patients develop ovarian cysts, and it failed to capture the significant metabolic dysfunction central to the condition. PMOS better reflects the complex interplay of reproductive and metabolic symptoms.
How will this affect current patients?
Current patients will continue receiving the same treatments, but the new name may help healthcare providers take a more comprehensive approach to care. The metabolic emphasis encourages screening for diabetes and cardiovascular risks.
When will medical records and systems be updated?
Major medical organizations are implementing the change over the next 12-18 months. Electronic health records and diagnostic coding systems are being updated to reflect the new terminology while maintaining continuity of care.
The transition to PMOS represents a significant step toward more accurate diagnosis and comprehensive care for millions of women worldwide. As healthcare systems adopt the new terminology, researchers expect improved coordination between specialties and better patient outcomes through recognition of the condition’s full metabolic scope.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
